Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £2.15m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Options Award

23 Dec 2025 07:00

RNS Number : 5646M
Physiomics PLC
23 December 2025
 

23 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Options Award

 

Physiomics plc (AIM: PYC), announces an award of share options (the "Options") over ordinary shares of 0.4 pence each in the capital of the Company ("Ordinary Shares"). The Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under the Company's existing share option scheme (the "Scheme"):

1. 1,516,044 Options with an exercise price of 0.41 pence, representing a 41% premium to the closing mid-market price per Ordinary Share on 22 December 2025. All these Options vest on the first anniversary of Mr Thissen's employment, being 1 July 2026.

2. 1,516,044 Options with exercise price of 0.79 pence, representing a 172% premium to the closing mid-market price per Ordinary Share on 22 December 2025. One third of these Options vest on each anniversary of Mr Thissen's employment (33.3% from 1 July 2026, 66.7% from 1 July 2027 and 100% from 1 July 2028)

3. 1,516,044 Options with an exercise price of 1.29 pence, representing a 345% premium to the closing mid-market price per Ordinary Share on 22 December 2025. These Options vest over the same time periods as described under (2) above.

All Options can be exercised within 10 years of the date of grant.

The total number of options issued to date under the Scheme is 4,548,132.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"As the Company pursues growth and a transition to cash generation, the establishment of a scalable second service line represents a significant milestone in this strategy. We are pleased to announce that following Jesse's appointment in July 2025, he has played an integral role in launching our new Biometrics service line. Within the first six months, he has secured and commenced delivery on three contracts supporting new therapies for infectious and immunological diseases. Jesse has demonstrated strong leadership in advancing the Biometrics service line and continues to contribute effectively across the broader organisation."

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZMZZZZKGKZZ
Date   Source Headline
8th Feb 20104:22 pmRNSHolding(s) in Company
29th Jan 20102:20 pmRNSTotal Voting Rights
29th Jan 20102:17 pmRNSHolding(s) in Company
22nd Jan 20101:14 pmRNSIssue of Equity
29th Dec 200910:53 amRNSResult of AGM
18th Dec 20091:06 pmRNSConversion of Loan Note
14th Dec 200912:46 pmRNSIssue of Equity
9th Dec 20097:47 amRNSHolding(s) in Company
4th Dec 200911:47 amRNSIssue of Equity
25th Nov 20099:16 amRNSHolding(s) in Company
19th Nov 20099:03 amRNSHolding(s) in Company
16th Nov 20094:50 pmRNSHolding(s) in Company
16th Nov 20097:00 amRNSPhysiomics Presentation
6th Nov 20094:30 pmRNSHolding(s) in Company
5th Nov 20094:22 pmRNSHolding(s) in Company
27th Oct 20094:18 pmRNSHolding(s) in Company
27th Oct 20099:35 amRNSHolding(s) in Company
23rd Oct 20094:23 pmRNSHolding(s) in Company
21st Oct 20099:06 amRNSHolding(s) in Company
20th Oct 20094:01 pmRNSHolding(s) in Company
20th Oct 20093:59 pmRNSHolding(s) in Company
16th Oct 20094:30 pmRNSRecent Price Movements
1st Oct 20093:02 pmRNSTrading Statement
18th Sep 200910:02 amRNSHolding(s) in Company
11th Sep 20093:52 pmRNSHolding(s) in Company
8th Sep 200912:37 pmRNSHolding(s) in Company - Replacement
7th Sep 20094:35 pmRNSHolding(s) in Company
3rd Sep 20099:12 amRNSHolding(s) in Company
28th Aug 20097:56 amRNSTotal Voting Rights
17th Aug 200910:01 amRNSHolding(s) in Company
6th Aug 20094:23 pmRNSConversion of Debt into Equity
24th Jul 20098:01 amRNSHolding(s) in Company
6th Jul 200911:52 amRNSHolding(s) in Company
2nd Jul 20097:53 amRNSHolding(s) in Company
26th Jun 20097:58 amRNSHolding(s) in Company
23rd Jun 20097:00 amRNSUpdate on EC funded TEMPO project
23rd Apr 20094:34 pmRNSHolding(s) in Company
22nd Apr 20094:43 pmRNSHolding(s) in Company
22nd Apr 20094:43 pmRNSHolding(s) in Company
20th Apr 20097:00 amRNSSeminar Presentation
2nd Apr 20097:00 amRNSLicense Agreement with Eli Lilly
1st Apr 20097:00 amRNSChange of Adviser
20th Mar 200912:33 pmRNSHolding(s) in Company
5th Mar 20093:20 pmRNSHolding(s) in Company
10th Feb 20097:30 amRNSHalf Yearly Report
26th Jan 200911:30 amRNSHolding(s) in Company
5th Jan 200910:45 amRNSHolding(s) in Company
19th Dec 200810:58 amRNSResult of AGM
19th Dec 200810:46 amRNSHolding(s) in Company
12th Dec 20087:30 amRNSPlacing of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.